Corey Goodman had been Pfizer's go-to guy for biotechnology. But now he's out.
Goodman was brought in 19 months ago as the senior vice president in charge of Pfizer's California biotechnology center, which was designed to spearhead the pharma giant's drive into the biotech sphere. In a SEC filing, Pfizer disclosed that Goodman has resigned from the company, without giving a reason for the departure. And in a conversation with Bloomberg, Goodman declined to say exactly what inspired his exit.
Earlier this month Pfizer announced that it would combine the biotech center with the biotechnology research arm of Wyeth into a new biotechnology division. A neuroscientist, Goodman had founded Exelixis and Renovis, which was sold to Evotec for $152 million in stock.
Goodman was paid a base salary of $725,000 and could earn up to $798,000 for a performance bonus. Pfizer also waived repayment of $1.7 million in replacement cash compensation which had been required if he left before completing two years with Pfizer.
- read the report from Bloomberg